StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)

Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –

United Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

United Therapeutics's pe ratio was 21.3× on Nov 11, 2026, against 18.4× a year earlier. Over the last 5 years it ranged from 11.0× to 21.4×, with a median of 16.3×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202621.3×+2.9
2025Dec 31, 202518.4×+2.9
2024Dec 31, 202415.5×+3.4
2023Dec 29, 202312.1×−6.8
2022Dec 30, 202218.9×+3.4
2021Jan 29, 202115.5×+1.1
2020Dec 31, 202014.4×+6.7
2019Apr 30, 20197.7×−1.1
2018Dec 31, 20188.8×−4.3
2017Dec 29, 201713.0×+3.4
2016Dec 30, 20169.7×−2.4
2015Dec 31, 201512.1×−26.0
2014Dec 31, 201438.1×+17.4
2013Dec 31, 201320.6×+9.6
2012Dec 31, 201211.0×−4.9
2011Dec 30, 201115.9×–

More United Therapeutics figures

See a number that looks wrong?